Fuling Technology
001356
KLT
831689
Hand Enterprise Solutions
300170
4
GRANDTECH
835184
5
Doushen(Beijing) Education & Technology Inc.
300010
US Stock MarketDetailed Quotes
APLS Apellis Pharmaceuticals
- 30.390
- +0.260+0.86%
Close Jan 22 16:00 ET
- 30.390
- 0.0000.00%
Pre 08:00 ET
3.78BMarket Cap-14.97P/E (TTM)
30.840High29.963Low1.32MVolume30.020Open30.130Pre Close40.00MTurnover1.56%Turnover RatioLossP/E (Static)124.39MShares71.90052wk High15.94P/B2.56BFloat Cap24.34052wk Low--Dividend TTM84.27MShs Float94.750Historical High--Div YieldTTM2.91%Amplitude11.450Historical Low30.409Avg Price1Lot Size
About Apellis Pharmaceuticals Company
Apellis Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company, which engages in the discovery, development, and commercialization of novel therapeutic compounds to treat diseases with high unmet needs. Its products include EMPAVELI and SYFOVRE. The company was founded by Candace Rose Depp, Pascal Deschatelets, Cedric Francois, and Alec Machiels on September 25, 2009 and is headquartered in Waltham, MA.
Company Profile
SymbolAPLS
Company NameApellis Pharmaceuticals
Listing DateNov 9, 2017
Issue Price14.00
Founded2009
CEODr. Cedric Francois, M.D.
MarketNASDAQ
Employees706
Fiscal Year Ends12-31
Address100 5th Avenue
CityWaltham
ProvinceMassachusetts
CountryUnited States of America
Zip Code02451-8703
Phone1-617-977-5700
Websitehttp://www.apellis.com
Company Executives
- Name
- Position
- Salary
- Dr. Cedric Francois, M.D.
- Director, Chief Executive Officer and President
- 10.37M
- Karen Lewis
- Chief People Officer
- --
- Dr. Jeffrey Eisele, PhD
- Chief Development Officer
- --
- Nur Nicholson
- Chief Technical Operations Officer
- --
- James George Chopas
- Vice President, Corporate Controller and Chief Accounting Officer
- --
- Dr. Caroline Baumal, M.D.
- Chief Medical Officer
- 4.43M
- Timothy E. Sullivan
- Chief Financial Officer and Treasurer
- 3.74M
- Pascal Deschatelets, PhD
- Chief Scientific Officer
- --
- Adam J. Townsend
- Chief Operating Officer
- 3.71M
- Mark Jeffrey DeLong
- Chief Business and Strategy Officer
- --
- David Acheson
- Executive Vice President, Commercial
- --
- Dr. Gerald L. Chan, Sc.D.
- Chairman of the Board
- 504.08K
- Paul Fonteyne, M.S.
- Independent Director
- 489.08K
- A. Sinclair Dunlop
- Independent Director
- 480.96K
- Keli Walbert
- Independent Director
- --
- Alec Machiels
- Independent Director
- 495.96K
- Stephanie Monaghan O’Brien
- Independent Director
- 488.46K
- David Watson
- General Counsel
- 4.89M
Trending Stocks
Investment Course
Top 5 Industries for Stock Trading under Trump's Second Term
Stocks & Industries to Watch Under Trump's Second Presidency
With mooomoo, find out which stocks and industries may benefit from Trump's second presidency, based on his first administration's track record.
Stocks & Industries to Watch Under Trump's Second Presidency
Key takeaways Tech stocks underwent substantial growth due to tax cuts and reduced corporate regulations in Trump's first term along with defense and aerospace
Discussing
Trump 2.0 Era: What's the next opportunity in the markets?
▪️Could Trump's crypto policies potentially benefit the crypto market? ▪️Might his tariff policies have a positive effect on Chinese stocks
Michael McCarthy CCO
Jan 3 11:57
Ask a strategist - Trump's first day